

LOCHT et al
Serial No. 08/765,287
January 23, 2004

AMENDMENTS TO THE CLAIMS:

The following claim listing is meant to replace all previous claim listing.

1. (Currently Amended): A recombinant DNA encoding an immunogenic fusion protein, wherein said recombinant DNA comprises a sequence (1) coding for a polypeptide heterologous with respect to a filamentous hemagglutinin of *Bordetella* (Fha) fused in the same reading frame with a sequence (2) placed upstream from said sequence (1), said sequence (2) coding for at least a part of the precursor of the Fha, this part comprising the site of interaction of the Fha with heparin, said sequence (2) being placed under the control of a promoter recognized by the polymerases of a cell transformed with said recombinant DNA and when introduced into a cell culture is expressed in said cell culture or exposed at the surface of cells, wherein said recombinant DNA is expressed as an immunogenic translational fusion protein.
2. (Currently Amended): The Recombinant recombinant DNA according to Claim 1, wherein the Fha is a Fha of *B. pertussis*.
3. (Currently Amended): The recombinant Recombinant DNA according to Claim 1, wherein the sequence (2) codes for the a mature Fha protein.

LOCHT et al
Serial No. 08/765,287
January 23, 2004

4. (Currently Amended): The recombinant Recombinant DNA according to Claim 3
4, wherein the sequence (2) results from truncation of the sequence coding for the mature Fha protein on its C-terminal side.
5. (Currently Amended): The recombinant Recombinant DNA according to Claim 1, further comprising a sequence (3) upstream from the sequence (1), this sequence (3) consisting essentially of ~~the a~~ truncated part of the mature protein, preferably supplemented by the signal sequence of the precursor.
6. (Currently Amended): The recombinant Recombinant DNA according to Claim 1, wherein the sequence (2) comprises the excretion signals of the sequence coding for the Fha and ~~the an~~ N-terminal domain of Fha homologous to the N-terminal domains of the hemolysins ShIA and HpmA of *Serratia marcescens* and *Proteus mirabilis*.
7. (Currently Amended): The recombinant DNA according to Claim 4, wherein the extension of the sequence (2) towards its C-terminus ~~will~~ does not exceed the length which would cause ~~the transformation of B. pertussis with this recombinant DNA then placed under the control of a promoter capable of being recognized by B. pertussis to that would~~ no longer permit the direct excretion of the recombinant protein then formed into the culture medium of ~~this B. pertussis~~.
8. (Currently Amended): The recombinant Recombinant DNA according to Claim 6, wherein the sequence (2) extends between the ATG corresponding to the

LOCHT et al
Serial No. 08/765,287
January 23, 2004

initiation codon for the translation of the Fha to a C-terminal nucleotide beyond nucleotide 907 in the direction of the translation and ~~preferably~~ not beyond the position 6292.

9. (Currently Amended): The recombinant Recombinant DNA according to Claim 8, wherein the encoded polypeptide does not react with anti-Fha antibodies ~~more particularly or with anti-Fha antibodies~~ directed against the epitopes of the C-terminal part of the mature Fha, located beyond the nucleotide site 2841 in the sense of translation.
10. (Currently Amended): The recombinant Recombinant DNA according to Claim 1, wherein the polypeptide encoded in the sequence (2) contains at least a specific attachment site of the Fha to the mucosa.
11. (Currently Amended): The recombinant Recombinant DNA according to Claim 1, wherein the sequence (1) codes for a polypeptide having vaccinating properties against a given pathogenic agent.
12. (Currently Amended): The recombinant Recombinant DNA according to Claim 1, wherein said DNA further comprises a promoter recognized by the polymerases of a cell transformable with a vector containing the recombinant DNA and allowing the expression of the sequences (1) and (2) provided that an accessory gene of the *fhaC* type is also expressed in this cell.

LOCHT et al
Serial No. 08/765,287
January 23, 2004

13. (Currently Amended): The recombinant Recombinant DNA according Claim 12, wherein the promoter is a promoter recognized by the polymerases of a bacterium of the *Bordetella* species, ~~in particular *B. pertussis*~~, which in the natural product regulates the expression of the Fha protein.
14. (Currently Amended): ~~A culture Culture of prokaryotic cells, in particular bacteria, transformed by a recombinant DNA according to Claim 11, wherein the promoter of the recombinant DNA is recognized by the polymerases of said prokaryotic cells~~.
15. (Currently Amended): ~~Culture~~ The culture according to Claim 14, wherein the cells belong to a *Bordetella* species and carry a fhaC gene expressable in these cells.

16-17: (Canceled)

18. (Currently Amended): ~~Get~~ The culture according to Claim 14, wherein the recombinant DNA is incorporated in the chromosomal DNA of said cells.
19. (Currently Amended): The culture ~~Culture~~ of cells according to Claim 14, characterized by the exposure of wherein the expression product of the sequence (1) is exposed at their the cell surface.

LOCHT et al
Serial No. 08/765,287
January 23, 2004

20.(Currently Amended): The culture Culture according to Claim 14, wherein the sequence (2) contains at least one attachment site for the Fha to the mucosa or to eukaryotic cells, particularly or to macrophages or epithelial cells.

21.(Currently Amended): The culture Cell according to Claim 20, characterized in that it wherein said culture is detoxified or attenuated.

22.(Currently Amended): An immunogenic immunogenic composition directed against a defined pathogenic agent comprising as an active principle cells of the culture according to Claim 18 in which the sequence (1) codes for an antigen characteristic of this said pathogenic agent.

23.-26: (Canceled)

27.(Currently Amended): A process Process for the production of a recombinant heterologous protein containing a defined polypeptide sequence comprising transforming the transformation of a culture of prokaryotic cells with a vector containing a recombinant DNA according to Claim 1, said prokaryotic cells also containing a nucleotide sequence coding for FhaC in a form capable of being which is expressed in it or also having been transformed to this end, followed by the culture of these cells culturing said prokaryotic cells; and the recovery of recovering the product excreted by the cells of this culture into their medium.

LOCHT et al
Serial No. 08/765,287
January 23, 2004

28.(Currently Amended): The process Process according to Claim 27, wherein said prokaryotic cells are *Bordetella*, in particular of the *B. pertussis* type.

29.(Currently Amended): The process Process according to Claim 27, characterized by the additional purification of further comprising purifying the excretion product by placing the culture medium in contact with heparin immobilized on an insoluble support and by the recovery of the recovering purified recombinant protein by dissociation of the complex which ~~is~~ said recombinant protein formed with heparin.

30.(Currently Amended): A recombinant DNA encoding a recombinant immunogenic polypeptide, wherein said recombinant DNA comprises a sequence (1) coding for an antigenic polypeptide or peptide fused in the same reading frame with a sequence (2) placed upstream from said sequence (1), said sequence (2) coding for at least a N-terminal region of the precursor of the Fha which contains the site of interaction of the Fha with heparin, said sequence (2) allowing the recombinant polypeptide, when said recombinant DNA is expressed as a translational fusion protein in a *B. pertussis* cell culture, to be secreted into the culture medium or exposed at the cell surface.

31.-33:(Cancelled)

34.(Currently Amended): A recombinant DNA comprising a sequence (1) coding for a polypeptide heterologous with respect to a filamentous hemmagglutinin of *Bordetella* (Fha) fused in the same reading frame with a sequence (2) placed

LOCHT et al
Serial No. 08/765,287
January 23, 2004

upstream from said sequence (1), said sequence (2) coding for at least a part of the precursor of the Fha; this part comprising at least the N-terminal region of a truncated mature Fha protein which contains the site of interaction of the Fha with heparin, said sequence (2), when placed under the control of a promoter recognized by the cellular polymerases of *B. pertussis* and introduced into a *B. pertussis* cell culture is expressed in this culture and excreted into the culture medium of these cells or exposed at the surface of these cells, wherein the resulting translational fusion protein facilitates the presentation of the antigen encoded by the heterologous sequence (1) to the mucosal immune system.

35. (Currently Amended): A vaccine composition for stimulating mucosal immunity comprising the cell culture according to Claim 22 14.

36. (Withdrawn): A vaccine composition for stimulating mucosal immunity comprising a recombinant protein encoded by the recombinant DNA of Claim 1.

37. (Currently Amended): A method for stimulating mucosal immunity, comprising ~~nasal administration~~ administering nasally to a subject in need thereof of a composition comprising the cell culture according to Claim 22 14.

38. (Withdrawn - Currently Amended): A method for stimulating mucosal immunity, comprising ~~nasal administration~~ administering nasally to a subject in need thereof of a composition comprising a recombinant protein encoded by the recombinant DNA of Claim 1.

LOCHT et al
Serial No. 08/765,287
January 23, 2004

39.(Previously Presented): The recombinant DNA according to Claim 30 or 34, wherein said sequence (1) codes for an antigenic polypeptide or peptide of a pathogenic agent.

40.(Currently Amended): A culture of bacterial cells belonging to a bacterial species other than *Bordetella* and transformed by a recombinant DNA encoding an immunogenic translational fusion protein comprising a sequence (1) coding for a polypeptide heterologous with respect to a filamentous hemagglutinin of *Bordetella* (Fha), said sequence (1) being fused in the same reading frame with a sequence (2) placed upstream from said sequence (1), said sequence (2) coding for at least a part of the precursor of the Fha, this part comprising the site of interaction of the Fha with heparin.

41.(Previously Presented): The cell culture according to Claim 40, wherein the cells belong to the species *E. coli*.

42.(Previously Presented): The culture of bacterial cells according to claim 40 wherein said polypeptide heterologous with respect to a filamentous hemagglutinin of *Bordetella* (Fha) has vaccinating properties against a given pathogenic agent, and said part of the precursor of the Fha comprises at least the N-terminal region of a truncated mature Fha protein.